Market revenue in 2024 | USD 39,824.0 million |
Market revenue in 2030 | USD 63,747.4 million |
Growth rate | 8.1% (CAGR from 2025 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 58.7% in 2024. Horizon Databook has segmented the India pharmaceutical market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
India's pharmaceutical industry has solidified its position as the "Pharmacy of the World," playing a crucial role in supplying vaccines, essential medicines, and medical supplies globally, particularly during the COVID-19 pandemic.
The sector has demonstrated strong innovation capabilities and remains an integral part of the global pharmaceutical value chain. India’s pharmaceutical exports have seen consistent growth, increasing by 8.36% from USD 2.13 billion in July 2023 to USD 2.31 billion in July 2024. Over the past decade, exports have surged from USD 15.07 billion in 2013-14 to USD 27.85 billion in FY 2023-24.
Ranking third globally in pharmaceutical production by volume, India exports to nearly 200 countries, with the U.S., Belgium, South Africa, the U.K., and Brazil as top destinations. With a projected 10-12% growth rate, the sector is expected to reach USD 100 billion by 2025, driven by a strong domestic manufacturing base and a growing demand for affordable medicines worldwide.
Horizon Databook provides a detailed overview of country-level data and insights on the India pharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into India pharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related industry reports found.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account